UPDATED Jan 24, 2023
Insider Buying Ratio of 80%-100%, with forecast growth, and a respectable return on equity.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
GSKGSK | UK£13.87 | -3.5% | -31.3% | UK£56.3b | UK£16.95 | PE12.6x | E2.2% | 7.2% | ||
AVTRAvantor | US$23.04 | 3.6% | -34.2% | US$15.5b | US$26.94 | PE26x | E12.4% | n/a | ||
3613Beijing Tong Ren Tang Chinese Medicine | HK$11.98 | 4.2% | -2.1% | HK$10.0b | HK$13.35 | PE18.1x | E11.9% | 2.3% | ||
ERISEris Lifesciences | ₹624.45 | -1.3% | -13.9% | ₹86.4b | ₹827.22 | PE21.4x | E12.1% | 1.2% | ||
CUVClinuvel Pharmaceuticals | AU$27.75 | 4.0% | 24.4% | AU$1.3b | AU$26.00 | PE65.7x | E30.3% | 0.1% |